SCHEMBL5442863

SCHEMBL5442863

COc1ccc(OCc2nnc(NC(=O)Nc3cc(C(F)(F)F)cc(C(F)(F)F)c3)s2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
PTPRE P23469 4/20 0.51
HPN P05981 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
RAF1 P04049 1/20 0.48
HTT P42858 3/20 0.47
MITF O75030 1/20 0.47
LMNA P02545 1/20 0.47
XBP1 P17861 1/20 0.47
PAX8 Q06710 1/20 0.47
NOD2 Q9HC29 1/20 0.47
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5435664 0.95 MAPT (0.59) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5442574 0.92 MAPT (0.58) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5450981 0.85 MAPT (0.59) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5444496 0.85 MAPT (0.60) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5447957 0.85 MAPT (0.56) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5441175 0.84 KMT2A (0.61) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5443077 0.82 HPN (0.64) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5449666 0.81 MAPT (0.59) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5444273 0.81 HPN (0.76) MAPTL3MBTL1MEN1KMT2ANPC1
SCHEMBL5438442 0.81 MAPT (0.52) MAPTL3MBTL1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191353-A1 Use of thiadiazoleurea derivatives MERCK PATENT GMBH (DE) 2007-08-16 US claimed
US-20070191353-A1 Use of thiadiazoleurea derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191353-A1 Use of thiadiazoleurea derivatives RAF1, ARAF, JAK1 MAPT 3983/4885L3MBTL1 1823/4885MEN1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.